{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:34:24Z","timestamp":1793414064233,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"am","delay-in-days":338,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.dmpk.2024.100995","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T19:08:10Z","timestamp":1704308890000},"page":"100995","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Sodium citrate buffer improves pazopanib solubility and absorption in gastric acid-suppressed rat model"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2356-3185","authenticated-orcid":false,"given":"Huda Jassim","family":"Muhammad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7777-7879","authenticated-orcid":false,"given":"Tsutomu","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6557-8514","authenticated-orcid":false,"given":"Arimi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2954-1532","authenticated-orcid":false,"given":"Yoshimichi","family":"Sai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.dmpk.2024.100995_bib1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/jjco\/hyy053","article-title":"Drug review: pazopanib","volume":"48","author":"Miyamoto","year":"2018","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"10.1016\/j.dmpk.2024.100995_bib2","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/clpt.2010.199","article-title":"A\u00a0phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors","volume":"88","author":"Heath","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.dmpk.2024.100995_bib3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s40262-017-0510-z","article-title":"Clinical pharmacokinetics and pharmacodynamics of pazopanib: towards optimized dosing","volume":"56","author":"Verheijen","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmpk.2024.100995_bib4","series-title":"(pazopanib hydrochloride) tablets: clinical pharmacologybiopharmaceutics review(s)","author":"Votrient","year":"2009"},{"issue":"5","key":"10.1016\/j.dmpk.2024.100995_bib5","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/cpt.1515","article-title":"The effect of using pazopanib with food vs. fasted on pharmacokinetics, patient safety, and preference (DIET Study)","volume":"106","author":"Lubberman","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2024.100995_bib6","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1021\/mp400403s","article-title":"Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development","volume":"10 11","author":"Smelick","year":"2013","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.dmpk.2024.100995_bib7","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3390\/curroncol28010076","article-title":"Proton pump inhibitors and oncologic treatment efficacy: a practical review of the literature for oncologists","volume":"28","author":"Uchiyama","year":"2021","journal-title":"Curr Oncol"},{"issue":"7","key":"10.1016\/j.dmpk.2024.100995_bib8","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1365-2036.2012.05014.x","article-title":"A\u00a0comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism","volume":"35","author":"Hunfeld","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dmpk.2024.100995_bib9","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00280-013-2164-3","article-title":"Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors","volume":"71","author":"Tan","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.dmpk.2024.100995_bib10","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1158\/1078-0432.CCR-18-2748","article-title":"Impact of Concomitant administration of gastric acid\u2013suppressive agents and pazopanib on outcomes in soft-tissue sarcoma patients treated within the EORTC 62043\/62072 Trials","volume":"25","author":"Mir","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.dmpk.2024.100995_bib11","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s40262-016-0503-3","article-title":"Tyrosinekinase inhibitors and proton pump inhibitors: an evaluation of treatment options","volume":"56","author":"Van Leeuwen","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.dmpk.2024.100995_bib12","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1002\/ijc.33469","article-title":"The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure","volume":"148","author":"Krens","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.dmpk.2024.100995_bib13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.critrevonc.2017.01.014","article-title":"Proton pump inhibitors in cancer patients: how useful they are? A review of the most common indications for their use","volume":"111","author":"Numico","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"10.1016\/j.dmpk.2024.100995_bib14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s40262-016-0503-3","article-title":"Tyrosine kinase inhibitors and proton pump inhibitors: an evaluation of treatment options","volume":"56","author":"Van Leeuwen","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1016\/j.dmpk.2024.100995_bib15","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2165\/00002018-200629090-00002","article-title":"Pharmacokinetic drug interaction profiles of proton pump inhibitors","volume":"29","author":"Blume","year":"2006","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.dmpk.2024.100995_bib16","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1177\/1078155210381794","article-title":"Should the concomitant use of erlotinib and acid-reducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents","volume":"17","author":"Duong","year":"2010","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"3","key":"10.1016\/j.dmpk.2024.100995_bib17","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.dmpk.2024.100995_bib18","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/cpt.1569","article-title":"Concomitant intake of coca-cola to manage the drug\u2013drug interaction between velpatasvir and omeprazole studied in healthy volunteers","volume":"106","author":"Seyen","year":"2019","journal-title":"Clinl Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.dmpk.2024.100995_bib19","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1128\/AAC.39.8.1671","article-title":"Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole","volume":"39","author":"Chin","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.dmpk.2024.100995_bib20","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2165\/11592630-000000000-00000","article-title":"Effect of pH and comedication on gastrointestinal absorption of posaconazole","volume":"50","author":"Walravens","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.dmpk.2024.100995_bib21","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.dmpk.2020.08.003","article-title":"Administration of erlotinib in apple juice overcomes decreased absorption in a rat model of gastric acid suppression","volume":"35","author":"Shimada","year":"2020","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"5","key":"10.1016\/j.dmpk.2024.100995_bib22","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00408-020-00390-x","article-title":"What is the role of over 100 excipients in over the counter (OTC) cough medicines?","volume":"198","author":"Eccles","year":"2020","journal-title":"Lung"},{"issue":"5","key":"10.1016\/j.dmpk.2024.100995_bib23","doi-asserted-by":"crossref","first-page":"972","DOI":"10.3390\/pharmaceutics14050972","article-title":"Citric acid: a multifunctional pharmaceutical excipient","volume":"14","author":"Lambros","year":"2022","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.dmpk.2024.100995_bib24","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1007\/s11095-016-1890-8","article-title":"Characterization of solid dispersion of itraconazole prepared by solubilization in concentrated aqueous solutions of weak organic acids and drying","volume":"33","author":"Parikh","year":"2016","journal-title":"Pharm Res (N Y)"},{"issue":"4","key":"10.1016\/j.dmpk.2024.100995_bib25","first-page":"553","article-title":"HPLC\u2013PDA analysis of pazopanib in rabbit plasma Using gefitib as internal standard","volume":"8","author":"Sakuntala","year":"2018","journal-title":"Int J Res Pharm Chem"},{"issue":"2","key":"10.1016\/j.dmpk.2024.100995_bib26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1254\/jjp.28.297","article-title":"Influence of surgical sympathectomy on gastric secretion and ulceration in rats","volume":"28","author":"Kasuya","year":"1978","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.dmpk.2024.100995_bib27","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/FTD.0000000000000121","article-title":"Development and validation of an HPLC-UV method for pazopanib quantification in human plasma and application to patients with cancer in routine clinical practice","volume":"37","author":"Escudero-Ort\u00edz","year":"2015","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.dmpk.2024.100995_bib28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijpharm.2018.04.037","article-title":"Solubility and bioavailability improvement of pazopanib hydrochloride","volume":"544","author":"Herbrink","year":"2018","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1016\/j.dmpk.2024.100995_bib29","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1021\/acs.molpharmaceut.8b00081","article-title":"Evaluation of pazopanib phase behavior following pH-induced supersaturation","volume":"15","author":"Sugihara","year":"2018","journal-title":"Mol Pharm"},{"issue":"8","key":"10.1016\/j.dmpk.2024.100995_bib30","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1124\/dmd.113.051193","article-title":"In\u00a0vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions","volume":"41","author":"Reyner","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2024.100995_bib31","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.9881","article-title":"Flavoured water consumption alters pharmacokinetic parameters and increases exposure of erlotinib and gefitinib in a preclinical study using Wistar rats","volume":"8","author":"Almomen","year":"2020","journal-title":"PeerJ"},{"issue":"12","key":"10.1016\/j.dmpk.2024.100995_bib32","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1200\/JCO.2015.65.2560","article-title":"Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer","volume":"34","author":"van Leeuwen","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.dmpk.2024.100995_bib33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1208\/s12249-020-01722-z","article-title":"Impact of food and drink administration vehicles on paediatric formulation performance: Part 1-effects on solubility of poorly soluble drugs","volume":"21","author":"Martir","year":"2020","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"10.1016\/j.dmpk.2024.100995_bib34","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1208\/s12249-008-9055-7","article-title":"Carvedilol: solubilization and cyclodextrin complexation: a technical note","volume":"9","author":"Loftsson","year":"2008","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"10.1016\/j.dmpk.2024.100995_bib35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40264-014-0144-0","article-title":"Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update","volume":"37","author":"Wedemeyer","year":"2014","journal-title":"Drug Saf"},{"issue":"8","key":"10.1016\/j.dmpk.2024.100995_bib36","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/FPC.0000000000000292","article-title":"PharmGKB summary: pazopanib pathway, pharmacokinetics","volume":"27","author":"Thorn","year":"2017","journal-title":"Pharmacogenetics Genom"},{"issue":"1","key":"10.1016\/j.dmpk.2024.100995_bib37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10637-008-9138-z","article-title":"The effect of P-gp (Mdr1a\/1b), BCRP (Bcrp1) and P-gp\/BCRP inhibitors on the in\u00a0vivo absorption, distribution, metabolism and excretion of imatinib","volume":"27","author":"Oostendorp","year":"2009","journal-title":"Invest N Drugs"},{"issue":"6","key":"10.1016\/j.dmpk.2024.100995_bib38","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00280-013-2164-3","article-title":"Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors","volume":"71","author":"Tan","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.dmpk.2024.100995_bib39","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1634\/theoncologist.2017-0578","article-title":"Effect of concomitant pH-elevating medications with pazopanib on progression-free survival and overall survival in patients with metastatic renal cell carcinoma","volume":"23","author":"McAlister","year":"2018","journal-title":"Oncol"},{"issue":"2","key":"10.1016\/j.dmpk.2024.100995_bib40","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/clpt.2012.73","article-title":"Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the achilles heel of targeted therapy?","volume":"92","author":"Budha","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmpk.2024.100995_bib41","first-page":"126","article-title":"A\u00a0guide for the administration of oral antineoplastic in patients with swallowing disorders","volume":"45","author":"Tejedor-Tejada","year":"2021","journal-title":"Farm Hosp"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436724000016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436724000016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:57:16Z","timestamp":1761163036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436724000016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":41,"alternative-id":["S1347436724000016"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2024.100995","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium citrate buffer improves pazopanib solubility and absorption in gastric acid-suppressed rat model","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2024.100995","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100995"}}